Clinical Topics

Metformin Promising for Improving Prostate Cancer Survival

by U.S. Medicine

September 9, 2018

MADISON, WI—Metformin, a commonly used drug for patients with Type 2 diabetes mellitus (DM), has shown promise in helping to treat prostate cancer (PCa), according to a new study.

The report in the Journal of Urology posited that metformin plus androgen deprivation therapy (ADT) might be beneficial in combination. To do that, a research team from the William S. Middleton Memorial Veterans Hospital and the University of Wisconsin-Madison performed a retrospective cohort of patients with advanced PCa.1

The investigators used the national VA database to identify all men diagnosed with PCa between 2000-2008 who were treated with ADT with follow-up through May of 2016. Excluded from the study were patients who had received ADT for six months or less or who had undergone the therapy concurrent with localized radiation.

In the cohort after exclusions were 87,344 patients divided into three cohorts: 61% were no DM, 22% were DM no metformin, and 17% were DM on metformin. Hazard ratios were calculated for overall survival (OS), skeletal-related events (SRE) and cancer-specific survival (CSS).

Results indicated that OS showed improved survival in DM on metformin (HR 0.82, 95% CI 0.78-0.86) vs. DM no metformin (HR 1.03, 95% CI 0.99-1.08) with no DM as referent group.

In addition, the study team noted, research revealed HR 0.82 (95% CI 0.72-0.93) for DM on metformin, while Cox proportional hazards analysis for CSS showed improved survival in DM on metformin (HR 0.70, 95% CI 0.64-0.77) vs. DM with no metformin (HR 0.93, 95% CI 0.85- 1.00), using no DM as a referent group.

“Metformin use in veterans with PCa receiving ADT is associated with improved oncologic outcomes,” study authors concluded. “This association should be evaluated in a prospective clinical trial.”

1. Richards KA, Liou JI, Cryns VL, Downs TM, Abel EJ, Jarrard DF. Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol. 2018 Jun 22. pii: S0022-5347(18)43412-X. doi: 10.1016/j.juro.2018.06.031. [Epub ahead of print] PubMed PMID: 29940252.

Comments are closed here.

Related Articles

VAMCs Usually as Good or Better Than Private Hospitals in Same Communities

Veterans are being given more options for obtaining care outside of the VA healthcare system. The question raised in new research is whether doing so improves care.

Report Could Add 23 Presumptive Conditions for Gulf War Veterans

A new report from the National Academies of Sciences, Engineering, and Medicine found that sufficient evidence supported an association between exposure to seven factors and detrimental reproductive effects in men or women who served in the Gulf War or developmental effects in their children.

U.S. Medicine Recommends

More From oncology


Melanomas Associated With Internal Malignancy Risk

Genetic and environmental risk factors have been associated with the development of multiple primary melanomas (MPM) but a new study questioned whether those patients might have increased predisposition to developing internal malignancies.


Some RCC Risk Factors Can Be Modified

Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study.


Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?


Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.


VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up